Magnetic Ganoderma Lucidum Spores (mGLS): A Novel Regulatable Targeted Drug Delivery System
Abstract In the past decades, many materials have been studied as carriers for targeted drug delivery. However, there is a need for utilizable and selective carrier materials with few side effects. Here, the magnetic Ganoderma Lucidum Spores (mGLS) as a highly efficient targeted drug delivery carrier were explored. Then the regulatable targeted drug delivery system was verified by loading and releasing of the 5-Fluorouracil (5-FU). The results showed that the maximum of the loaded 5-FU reached 250.23 mg·$ g^{−1} $ in the mGLS. The cumulative release of the 5-FU for the drug delivery system could reach 80.11% and 67.14% in the PBS and HCl after 48 h, respectively. In addition, this system showed the good pharmacokinetic properties in vivo. After 12 h, the blood concentration in the 5-FUmGLS group kept at 5.3 µg·$ mL^{−1} $ and was four times higher than that in the 5-FU group. In summary, the GLS as a natural microscale core-shell structures appears the striking application in carrier material for oral drug delivery..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Journal of bionic engineering - 18(2021), 4 vom: Juli, Seite 915-926 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Han, Bin [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: |
50.14 / Technik in Beziehung zu anderen Gebieten / Technik in Beziehung zu anderen Gebieten |
|---|---|
| Themen: |
5-FU |
| Anmerkungen: |
© Jilin University 2021 |
|---|
| doi: |
10.1007/s42235-021-0059-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2078338052 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2078338052 | ||
| 003 | DE-627 | ||
| 005 | 20240403165736.0 | ||
| 007 | tu | ||
| 008 | 221220s2021 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s42235-021-0059-2 |2 doi | |
| 035 | |a (DE-627)OLC2078338052 | ||
| 035 | |a (DE-He213)s42235-021-0059-2-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 660 |a 620 |q VZ |
| 082 | 0 | 4 | |a 570 |a 004 |q VZ |
| 084 | |a 50.14 |2 bkl | ||
| 100 | 1 | |a Han, Bin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Magnetic Ganoderma Lucidum Spores (mGLS): A Novel Regulatable Targeted Drug Delivery System |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Jilin University 2021 | ||
| 520 | |a Abstract In the past decades, many materials have been studied as carriers for targeted drug delivery. However, there is a need for utilizable and selective carrier materials with few side effects. Here, the magnetic Ganoderma Lucidum Spores (mGLS) as a highly efficient targeted drug delivery carrier were explored. Then the regulatable targeted drug delivery system was verified by loading and releasing of the 5-Fluorouracil (5-FU). The results showed that the maximum of the loaded 5-FU reached 250.23 mg·$ g^{−1} $ in the mGLS. The cumulative release of the 5-FU for the drug delivery system could reach 80.11% and 67.14% in the PBS and HCl after 48 h, respectively. In addition, this system showed the good pharmacokinetic properties in vivo. After 12 h, the blood concentration in the 5-FUmGLS group kept at 5.3 µg·$ mL^{−1} $ and was four times higher than that in the 5-FU group. In summary, the GLS as a natural microscale core-shell structures appears the striking application in carrier material for oral drug delivery. | ||
| 650 | 4 | |a Magnetic Ganoderma Lucidum Spores (mGLS) | |
| 650 | 4 | |a sustained release | |
| 650 | 4 | |a 5-FU | |
| 650 | 4 | |a drug delivery | |
| 700 | 1 | |a Weng, Zhankun |4 aut | |
| 700 | 1 | |a Wu, Yuhan |4 aut | |
| 700 | 1 | |a Zhao, Xin |4 aut | |
| 700 | 1 | |a Li, Jingmei |4 aut | |
| 700 | 1 | |a Zhang, Qinhan |4 aut | |
| 700 | 1 | |a Qu, Kaige |4 aut | |
| 700 | 1 | |a Liang, Bojian |4 aut | |
| 700 | 1 | |a Zhou, Fenguo |4 aut | |
| 700 | 1 | |a Liu, Guixia |4 aut | |
| 700 | 1 | |a Wang, Zuobin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of bionic engineering |d Springer Singapore, 2006 |g 18(2021), 4 vom: Juli, Seite 915-926 |w (DE-627)667035931 |w (DE-600)2625220-X |w (DE-576)505266687 |x 1672-6529 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2021 |g number:4 |g month:07 |g pages:915-926 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s42235-021-0059-2 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a GBV_ILN_2018 | ||
| 936 | b | k | |a 50.14 |j Technik in Beziehung zu anderen Gebieten |j Technik in Beziehung zu anderen Gebieten |q VZ |
| 951 | |a AR | ||
| 952 | |d 18 |j 2021 |e 4 |c 07 |h 915-926 | ||